![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C31H31N5O2S2 |
Molar mass | 569.74 g·mol−1 |
3D model (JSmol) | |
| |
|
SRT-3025 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. It has been investigated as a potential treatment for osteoporosis, [1] [2] [3] [4] [5] and anemia. [6] [7]